WO2008020651A1 - antagoniste de récepteur P2X4 - Google Patents

antagoniste de récepteur P2X4 Download PDF

Info

Publication number
WO2008020651A1
WO2008020651A1 PCT/JP2007/066323 JP2007066323W WO2008020651A1 WO 2008020651 A1 WO2008020651 A1 WO 2008020651A1 JP 2007066323 W JP2007066323 W JP 2007066323W WO 2008020651 A1 WO2008020651 A1 WO 2008020651A1
Authority
WO
WIPO (PCT)
Prior art keywords
receptor
pain
antagonist
pharmaceutical composition
paroxetine
Prior art date
Application number
PCT/JP2007/066323
Other languages
English (en)
Japanese (ja)
Inventor
Kazuhide Inoue
Makoto Tsuda
Kenichiro Nagata
Original Assignee
Kyushu University, National University Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyushu University, National University Corporation filed Critical Kyushu University, National University Corporation
Priority to JP2008529899A priority Critical patent/JPWO2008020651A1/ja
Publication of WO2008020651A1 publication Critical patent/WO2008020651A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention a pour objet un antagoniste d'un récepteur P2X4, par exemple un inhibiteur sélectif de recapture de la sérotonine (SSRI) tel que paroxétine, fluoxétine, fluvoxamine et citalopram.
PCT/JP2007/066323 2006-08-17 2007-08-16 antagoniste de récepteur P2X4 WO2008020651A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008529899A JPWO2008020651A1 (ja) 2006-08-17 2007-08-16 Ｐ２ｘ４受容体アンタゴニスト

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83875906P 2006-08-17 2006-08-17
US60/838,759 2006-08-17

Publications (1)

Publication Number Publication Date
WO2008020651A1 true WO2008020651A1 (fr) 2008-02-21

Family

ID=39082170

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/066323 WO2008020651A1 (fr) 2006-08-17 2007-08-16 antagoniste de récepteur P2X4

Country Status (2)

Country Link
JP (1) JPWO2008020651A1 (fr)
WO (1) WO2008020651A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012060397A1 (fr) 2010-11-05 2012-05-10 国立大学法人九州大学 Agent préventif ou thérapeutique de la douleur associée au zona en phase aiguë
EP2716302A1 (fr) * 2011-05-25 2014-04-09 Kyushu University Agent prophylactique ou thérapeutique pour la douleur neuropathique associée au syndrome de guillain-barré
WO2022030428A1 (fr) 2020-08-03 2022-02-10 日本ケミファ株式会社 Composition pharmaceutique pour la prévention, la suppression ou le traitement de symptômes associés à une réaction allergique
IT202100025124A1 (it) 2021-09-30 2023-03-30 Univ Degli Studi Di Firenze Medicamento per uso nel prevenire o trattare il dolore nocicettivo e/o viscerale
WO2023054578A1 (fr) 2021-09-30 2023-04-06 日本ケミファ株式会社 Agent prophylactique ou thérapeutique pour des maladies respiratoires
US11918589B2 (en) 2016-04-28 2024-03-05 Nippon Chemiphar Co., Ltd. Medicament for treatment of multiple sclerosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530345A (ja) * 2000-04-07 2003-10-14 ファイザー・プロダクツ・インク 急性、慢性疼痛及び／またはニューロパシー性疼痛及び片頭痛の治療のための医薬組成物
WO2004085440A1 (fr) * 2003-03-24 2004-10-07 Bayer Healthcare Ag Derives de benzofuro-1,4-diazepin-2-one

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530345A (ja) * 2000-04-07 2003-10-14 ファイザー・プロダクツ・インク 急性、慢性疼痛及び／またはニューロパシー性疼痛及び片頭痛の治療のための医薬組成物
WO2004085440A1 (fr) * 2003-03-24 2004-10-07 Bayer Healthcare Ag Derives de benzofuro-1,4-diazepin-2-one

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BOMHOLT S.F. ET AL.: "Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain", NEUROPHARMACOLOGY, vol. 48, no. 2, 2005, pages 252 - 263, XP002460895 *
GIDAL B. ET AL.: "New and emerging treatment options for neuropathic pain", THE AMERICAN JOURNAL OF MANAGED CARE, vol. 12, no. 9, SUPPL. 1, June 2006 (2006-06-01), pages S269 - S278, XP003021081 *
LABUDA C.J. ET AL.: "Pharmacological evaluation of the selective spinal nerve ligation model of neuropathic pain in the rat", JOURNAL OF NEUROSCIENCE METHODS, vol. 144, no. 2, 2005, pages 175 - 181, XP004903463 *
OBATA H. ET AL.: "The Monoamine-Mediated Antiallodynic Effects of Intrathecally Administered Minacipran, a Serotonin Noradrenaline Reuptake Inhibitor, in a Rat Model of Neuropathic Pain", ANESTHESIA & ANALGESIA, vol. 100, no. 5, 2005, pages 1406 - 1410, XP003021084 *
SINGH V.P. ET AL.: "Fluoxetine, a selective serotonin reuptake inhibitor modulates inflammatory and neuropathic pain in the rat", INFLAMMOPHARMACOLOGY, vol. 9, no. 3, 2002, pages 219 - 228, XP003021083 *
STONE K.J. ET AL.: "Off-label applications for SSRIs", AMERICAN FAMILY PHYSICIAN, vol. 68, no. 3, 2003, pages 498 - 504, XP003021082 *
TSUDA M. ET AL.: "P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury", NATURE, vol. 424, no. 6950, 2003, pages 778 - 783, XP002376086 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017014224A (ja) * 2010-11-05 2017-01-19 国立大学法人九州大学 帯状疱疹関連痛の急性期疼痛の予防又は治療剤
EP3132803A2 (fr) 2010-11-05 2017-02-22 Kyushu University Agent préventif ou thérapeutique de la douleur associée au zona en phase aiguë
US9561235B2 (en) 2010-11-05 2017-02-07 Kyushu University Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
WO2012060397A1 (fr) 2010-11-05 2012-05-10 国立大学法人九州大学 Agent préventif ou thérapeutique de la douleur associée au zona en phase aiguë
EP2716302A4 (fr) * 2011-05-25 2014-11-05 Univ Kyushu Agent prophylactique ou thérapeutique pour la douleur neuropathique associée au syndrome de guillain-barré
JPWO2012161301A1 (ja) * 2011-05-25 2014-07-31 国立大学法人九州大学 ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤
EP2716302A1 (fr) * 2011-05-25 2014-04-09 Kyushu University Agent prophylactique ou thérapeutique pour la douleur neuropathique associée au syndrome de guillain-barré
JP2017119702A (ja) * 2011-05-25 2017-07-06 国立大学法人九州大学 ギラン・バレー症候群に伴う神経因性疼痛の予防又は治療剤
US11918589B2 (en) 2016-04-28 2024-03-05 Nippon Chemiphar Co., Ltd. Medicament for treatment of multiple sclerosis
WO2022030428A1 (fr) 2020-08-03 2022-02-10 日本ケミファ株式会社 Composition pharmaceutique pour la prévention, la suppression ou le traitement de symptômes associés à une réaction allergique
IT202100025124A1 (it) 2021-09-30 2023-03-30 Univ Degli Studi Di Firenze Medicamento per uso nel prevenire o trattare il dolore nocicettivo e/o viscerale
WO2023054578A1 (fr) 2021-09-30 2023-04-06 日本ケミファ株式会社 Agent prophylactique ou thérapeutique pour des maladies respiratoires
WO2023052518A1 (fr) 2021-09-30 2023-04-06 Universita' Degli Studi Di Firenze Médicament comprenant un antagoniste du récepteur p2x4 pour la prévention ou le traitement de la douleur nociceptive et/ou de la douleur viscérale

Also Published As

Publication number Publication date
JPWO2008020651A1 (ja) 2010-01-07

Similar Documents

Publication Publication Date Title
JP5673973B2 (ja) 痛みを緩和するための新規な方法および組成物
US20040266776A1 (en) Methods of preventing and reducing the severity of stress-associated conditions
US20220184075A1 (en) Pharmaceutical composition containing hdac6 inhibitor as active ingredient for prevention or treatment of itching
JP2012025756A (ja) 選択的ｓ１ｐ１レセプターアゴニストの投与法
WO2008020651A1 (fr) antagoniste de récepteur P2X4
EP2156833A1 (fr) Agent prophylactique ou thérapeutique destiné à une maladie oculaire postérieure comprenant un agoniste qui n'est pas dérivé de l'ergot de seigle sélectif du récepteur d2 en tant que principe actif
CA3025268A1 (fr) Promedicaments a base d'agonistes de trpv1 phenoliques en association avec des anesthesiques locaux et des vasoconstricteurs pour ameliorer une anesthesie locale
US20160184340A1 (en) The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
US20090326014A1 (en) Use of 5-ht7 receptor agonists for the treatment of pain
MXPA02007155A (es) Combinaciones farmaceuticas para el tratamiento de enfermedades neurodegenerativas.
US20070105940A1 (en) Method for treating pain
Woo et al. Conscious sedation during ophthalmic surgery under local anesthesia
WO2007049825A1 (fr) Antagoniste du recepteur p2x4antagoniste du recepteur p2x4antagoniste du recepteur p2x4
WO2017041112A1 (fr) Combinaisons de kétamine et d'inhibiteur du cytochrome p 450
WO2010110428A1 (fr) Agent pour prévenir et/ou traiter le prurit
US20070259945A1 (en) Method for treating pain
Sonsalla The role of N-methyl-D-aspartate receptors in dopaminergic neuropathology produced by the amphetamines
US20140094446A1 (en) Cyclic Amino Acids for the Treatment of Pain
JP4428481B2 (ja) 神経因性疼痛治療剤
JP4362457B2 (ja) 神経因性疼痛治療剤
JPWO2005070437A1 (ja) 疼痛の治療のための医薬
US20240016790A1 (en) Methods of using a phenoxypropylamine compound to treat pain
JPWO2003047591A1 (ja) 肺高血圧症予防治療剤
EP1778248A1 (fr) Composition contenant un derive de la thio-uree destinee a prevenir ou a traiter des maladies de la peau prurigineuses ou irritantes
WO2007026928A1 (fr) Agent therapeutique pour une douleur neuropathique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07805982

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 2008529899

Country of ref document: JP

122 Ep: pct application non-entry in european phase

Ref document number: 07805982

Country of ref document: EP

Kind code of ref document: A1